Sources

5 Total Sources

Novo Shares Drop 5.4% as 2032 Semaglutide Patent Cliff Overshadows $23 Billion Growth Plan

Left75%

Center25%

Novo Shares Drop Amid Patent Expiry Concerns, New Growth Strategy

AskTraders1h ago

Novo Nordisk Shares Slide 7% as Investor Day Fails to Answer Growth Doubts | AskTraders.com %

Novo Shares Drop Premarket on Unimpressive Weight Loss Market Goals

Novo Nordisk Stock Falls 5.4% After 2030 Strategy Disappoints Investors

Yahoo Finance4h ago

Novo Nordisk Stock Drops Over 5% Amid Pipeline Concerns, Competition